Home > DARE Reviews > Bleeding risk in atrial fibrillation...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis

Review published: 2013.

Bibliographic details: Lopes LC, Spencer FA, Neumann I, Ventresca M, Ebrahim S, Zhou Q, Bhatnaga N, Schulman S, Eikelboom J, Guyatt G.  Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis. Clinical Pharmacology and Therapeutics 2013; 94(3): 367-375. [PubMed: 23670121]

Abstract

Vitamin K antagonists (VKAs) prevent stroke in atrial fibrillation (AF) at the cost of bleeding risk. To determine major bleeding rates in AF patients, we conducted a systematic review that identified 51 eligible studies including more than 342,699 patients. The pooled estimate of the rate of major bleeding was 2.51 (99% confidence interval: 2.03-3.11) bleeds per 100 patient-years. The results represent the best estimates of bleeding risk that most patients contemplating VKA use may expect.

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2014 University of York.

PMID: 23670121

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...